5. Progressive supranuclear palsy
82 clinical trials, 107 drugs (DrugBank: 36 drugs), 60 drug target genes, 90 drug target pathways
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04539041 (ClinicalTrials.gov) | January 19, 2021 | 25/8/2020 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy | A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy (PSP) | Drug: antisense oligonucleotide;Drug: placebo | Novartis Pharmaceuticals | NULL | Not yet recruiting | 40 Years | 75 Years | All | 64 | Phase 1 | NULL |
| 2 | NCT04253132 (ClinicalTrials.gov) | January 1, 2021 | 17/12/2019 | Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks | A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Tolfenamic Acid;Drug: Placebos | NeuroTau, Inc. | The Cleveland Clinic | Not yet recruiting | 40 Years | 85 Years | All | 24 | Phase 1;Phase 2 | United States |
| 3 | NCT04658199 (ClinicalTrials.gov) | December 2020 | 1/12/2020 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: UCB0107 (bepranemab) | UCB Biopharma SRL | NULL | Not yet recruiting | 18 Years | N/A | All | 24 | Phase 1 | NULL |
| 4 | NCT04193527 (ClinicalTrials.gov) | July 2020 | 2/12/2019 | A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients | A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls | Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP) | Drug: DaTSCAN™ Ioflupane (123I) Injection | GE Healthcare | PPD | Not yet recruiting | 40 Years | 80 Years | All | 172 | Phase 3 | China |
| 5 | NCT04008355 (ClinicalTrials.gov) | June 22, 2020 | 18/6/2019 | A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: AZP2006 oral solution;Drug: Placebo oral solution | AlzProtect SAS | NULL | Recruiting | 40 Years | 80 Years | All | 36 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03446807 (ClinicalTrials.gov) | January 2020 | 20/2/2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not yet recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 7 | NCT04185415 (ClinicalTrials.gov) | December 3, 2019 | 2/12/2019 | A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: bepranemab;Drug: Placebo | UCB Biopharma SRL | NULL | Active, not recruiting | 40 Years | N/A | All | 25 | Phase 1 | Belgium;Germany;Spain;United Kingdom |
| 8 | NCT04184063 (ClinicalTrials.gov) | September 16, 2019 | 29/7/2019 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) | Progressive Supranuclear Palsy;Multiple System Atrophy | Drug: NBMI;Other: Placebo | EmeraMed | NULL | Recruiting | 40 Years | 85 Years | All | 16 | Phase 2 | Slovenia |
| 9 | NCT03926702 (ClinicalTrials.gov) | June 18, 2019 | 22/4/2019 | Tau Imaging With JNJ067 | Tau Imaging With JNJ067 | Alzheimer Disease;Mild Cognitive Impairment;Progressive Supranuclear Palsy | Drug: Radiopharmaceuticals | University of California, Berkeley | University of California, San Francisco | Active, not recruiting | 50 Years | N/A | All | 18 | Early Phase 1 | United States |
| 10 | NCT04014387 (ClinicalTrials.gov) | June 2, 2019 | 11/4/2019 | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment | Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule | University of California, San Francisco | US Department of Veterans Affairs | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | JPRN-UMIN000036908 | 2019/05/31 | 31/05/2019 | A dementia study by 11C-PiB, 18F-FDG PET | A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET | mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc. | 11C-PiB, 18F-FDG PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
| 12 | JPRN-jRCTs051180214 | 29/03/2019 | 27/03/2019 | The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease | The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease | Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy | Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously | Itoh Yoshiaki | NULL | Recruiting | Ages 20 and over | N/A | Both | 100 | N/A | Japan |
| 13 | NCT03413319 (ClinicalTrials.gov) | April 17, 2018 | 23/1/2018 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12 | AbbVie | NULL | Completed | 18 Years | N/A | All | 3 | Phase 1 | United States |
| 14 | NCT03545789 (ClinicalTrials.gov) | March 12, 2018 | 15/3/2018 | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers | Healthy Volunteers;Alzheimer Disease;Progressive Supranuclear Palsy | Drug: [18F]MNI-958 | Invicro | NULL | Completed | 18 Years | 55 Years | All | 16 | Phase 1 | United States |
| 15 | NCT03391765 (ClinicalTrials.gov) | January 24, 2018 | 2/1/2018 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12 | AbbVie | NULL | Completed | 40 Years | N/A | All | 143 | Phase 2 | United States;Australia;Canada;Italy;Japan;France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03625128 (ClinicalTrials.gov) | January 2, 2018 | 12/7/2018 | 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment | Drug: F-18 | Chang Gung Memorial Hospital | NULL | Completed | 20 Years | 90 Years | All | 36 | Early Phase 1 | Taiwan |
| 17 | NCT03545126 (ClinicalTrials.gov) | August 21, 2017 | 12/3/2018 | Human CNS Tau Kinetics in Tauopathies | Human CNS Tau Kinetics in Tauopathies | Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation) | Other: 13C6 Leucine | Washington University School of Medicine | Association of Frontotemporal Degeneration;Tau Consortium | Recruiting | 18 Years | N/A | All | 32 | United States | |
| 18 | NCT03068468 (ClinicalTrials.gov) | June 1, 2017 | 27/2/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Terminated | 41 Years | 86 Years | All | 490 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom |
| 19 | NCT03174938 (ClinicalTrials.gov) | May 15, 2017 | 28/5/2017 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
| 20 | EUCTR2017-000094-36-SE (EUCTR) | 31/03/2017 | 30/01/2017 | The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders | The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders | Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-RO6958948 Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl | Skåne University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Sweden | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02985879 (ClinicalTrials.gov) | December 12, 2016 | 1/12/2016 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: placebo;Drug: ABBV-8E12 | AbbVie | NULL | Completed | 40 Years | N/A | All | 378 | Phase 2 | United States;Australia;Canada;France;Germany;Italy;Japan;Spain |
| 22 | NCT03058965 (ClinicalTrials.gov) | November 29, 2016 | 12/1/2017 | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | Alzheimer Disease;Healthy Volunteers;Progressive Supranuclear Palsy | Drug: [18F]MNI-958;Drug: [18F]Florbetapir;Drug: DaTscan | Molecular NeuroImaging | NULL | Completed | 50 Years | 90 Years | All | 12 | Early Phase 1 | United States |
| 23 | NCT03080051 (ClinicalTrials.gov) | August 2016 | 12/1/2017 | Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers | Progressive Supranuclear Palsy;Alzheimer Disease;Healthy Volunteers | Drug: [18F]MNI-952;Drug: [18F]Florbetapir | Molecular NeuroImaging | NULL | Completed | 18 Years | 90 Years | All | 6 | Early Phase 1 | United States |
| 24 | NCT02839642 (ClinicalTrials.gov) | July 26, 2016 | 30/6/2016 | Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy | RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial | Progressive Supranuclear Palsy (PSP) | Drug: Rivastigmine;Drug: Placebo | Assistance Publique Hopitaux De Marseille | NULL | Recruiting | 41 Years | 80 Years | All | 106 | Phase 3 | France |
| 25 | NCT02994719 (ClinicalTrials.gov) | March 1, 2016 | 21/12/2015 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | NULL | Active, not recruiting | 18 Years | 85 Years | All | 120 | United States | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02658916 (ClinicalTrials.gov) | February 22, 2016 | 13/1/2016 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003 | Supranuclear Palsy, Progressive | Drug: BIIB092 | Biogen | NULL | Terminated | 41 Years | 86 Years | All | 47 | Phase 1 | United States |
| 27 | NCT02605785 (ClinicalTrials.gov) | November 2015 | 3/11/2015 | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: F-18 AV 1451 | Mayo Clinic | NULL | Recruiting | 40 Years | N/A | All | 134 | N/A | United States |
| 28 | NCT02460094 (ClinicalTrials.gov) | October 2, 2015 | 20/5/2015 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Completed | 41 Years | 86 Years | All | 48 | Phase 1 | United States |
| 29 | NCT02494024 (ClinicalTrials.gov) | July 2015 | 30/6/2015 | Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Single dose C2N-8E12;Drug: Single dose placebo | C2N Diagnostics | NULL | Completed | 50 Years | 85 Years | All | 32 | Phase 1 | United States |
| 30 | NCT02460731 (ClinicalTrials.gov) | May 2015 | 19/5/2015 | Young Plasma Transfusions for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Biological: Fresh Frozen Plasma | University of California, San Francisco | NULL | Completed | 50 Years | 85 Years | All | 6 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02531360 (ClinicalTrials.gov) | May 2015 | 9/6/2015 | Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies | Alzheimer's Disease (AD);Progressive Supranuclear Palsy (PSP);Cortical Basal Syndrome (CBS);Frontal Temporal Dementia (FTD) | Drug: [18F]MNI-815 (MNI-815) | Molecular NeuroImaging | Piramal Imaging SA | Completed | 50 Years | 90 Years | Both | 7 | Phase 0 | United States |
| 32 | NCT02422485 (ClinicalTrials.gov) | April 2015 | 9/4/2015 | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Salsalate | Adam Boxer | NULL | Unknown status | 50 Years | 85 Years | All | 10 | Phase 1 | United States |
| 33 | EUCTR2014-000422-38-SE (EUCTR) | 19/09/2014 | 05/08/2014 | A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau | An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions. MedDRA version: 17.0;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-AV-1451 | Skåne University Hospital, Region Skåne | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Sweden | ||||
| 34 | NCT02167594 (ClinicalTrials.gov) | August 12, 2014 | 17/6/2014 | Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers | 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Flortaucipir F18;Procedure: Brain PET scan | Avid Radiopharmaceuticals | NULL | Completed | 50 Years | 85 Years | All | 29 | Phase 1 | United States |
| 35 | NCT02133846 (ClinicalTrials.gov) | May 2014 | 6/5/2014 | Safety Study of TPI-287 to Treat CBS and PSP | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy | Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD) | Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2 | University of California, San Francisco | CBD Solutions;Tau Consortium | Completed | 50 Years | 85 Years | All | 44 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02103894 (ClinicalTrials.gov) | February 2014 | 12/2/2014 | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects | Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects | Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies | Drug: [18F]T807 ([18F]MNI-777) | Molecular NeuroImaging | Institute for Neurodegenerative Disorders | Completed | 18 Years | 85 Years | Both | 16 | Phase 1 | United States |
| 37 | EUCTR2010-019159-23-GB (EUCTR) | 22/12/2010 | 08/10/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2;Phase 3 | France;United States;Canada;Australia;Germany;United Kingdom | |||
| 38 | EUCTR2010-019159-23-DE (EUCTR) | 08/11/2010 | 27/08/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 INN or Proposed INN: Davunetide | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2;Phase 3 | France;United States;Canada;Australia;Germany;United Kingdom | ||
| 39 | NCT01110720 (ClinicalTrials.gov) | October 2010 | 23/4/2010 | Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Davunetide;Drug: Placebo | Allon Therapeutics | NULL | Completed | 41 Years | 85 Years | Both | 313 | Phase 2;Phase 3 | United States;Australia;Canada;France;Germany;United Kingdom |
| 40 | NCT01537549 (ClinicalTrials.gov) | September 14, 2010 | 9/1/2012 | Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy | An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers | Progressive Supranuclear Palsy | Drug: alpha-lipoic acid and L-acetyl carnitine | Weill Medical College of Cornell University | NULL | Completed | 40 Years | 75 Years | All | 11 | Phase 1;Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT01056965 (ClinicalTrials.gov) | January 2010 | 21/1/2010 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies | Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia | Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray | University of California, San Francisco | NULL | Completed | 40 Years | 85 Years | All | 12 | Phase 1 | United States |
| 42 | EUCTR2009-013097-40-ES (EUCTR) | 17/11/2009 | 29/07/2009 | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Parálisis Supranuclear Progresiva leve o moderada MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | Spain;Germany;United Kingdom | |||
| 43 | NCT00703677 (ClinicalTrials.gov) | September 2008 | 20/6/2008 | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration | Progressive Supranuclear Palsy;Corticobasal Degeneration | Drug: Lithium | Westat | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 40 Years | 80 Years | All | 17 | Phase 1;Phase 2 | United States;United Kingdom |
| 44 | NCT00382824 (ClinicalTrials.gov) | September 2006 | 28/9/2006 | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study | Progressive Supranuclear Palsy | Dietary Supplement: Coenzyme Q10;Other: Placebo | Lahey Clinic | NULL | Completed | 30 Years | N/A | All | 61 | N/A | United States |
| 45 | NCT00328874 (ClinicalTrials.gov) | May 2006 | 21/5/2006 | Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy | Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Coenzyme Q10 | German Parkinson Study Group (GPS) | MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical Center | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00605930 (ClinicalTrials.gov) | April 2004 | 14/1/2008 | A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy | Dietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: Placebo | University of Louisville | NULL | Completed | N/A | N/A | All | 20 | N/A | United States |
| 47 | NCT00532571 (ClinicalTrials.gov) | January 2004 | 18/9/2007 | Effects of Coenzyme Q10 in PSP and CBD | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study | Progressive Supranuclear Palsy;Neurological Disorders | Drug: CoQ10 | Lahey Clinic | NULL | Completed | 40 Years | N/A | All | Phase 2;Phase 3 | United States |